GeekWire
MARCH 8, 2022
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We million in 2020.
GeekWire
FEBRUARY 15, 2022
Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 Net loss for 2021 came in at $207.3 million in the fourth quarter, up 26%, with a net loss of $61.4 million available in cash, cash equivalents and marketable securities. GeekWire Photo / Charlotte Schubert).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeekWire
FEBRUARY 3, 2021
Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Even without the IPO, Sana is sitting on a large cash pile.
GeekWire
JANUARY 13, 2021
Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. It reported $459 million in cash, cash equivalents and marketable securities at the end of September 2020. And like many biotechnology companies it is losing money. Sana CEO Steve Harr (Sana photo).
GeekWire
JUNE 30, 2021
Securities and Exchange Commission. The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. Net losses were $14.4 2020 revenue was $4.7 million, up from $2 million for 2019. 2020 revenue was $4.7
GeekWire
JULY 7, 2021
Securities and Exchange Commission. Pacific Northwest biotechs that have gone public this year include Sana Biotechnology, which raised $587 million in its February IPO and Impel NeuroPharma, which raised $80 million through its IPO in April. Net losses were $5.3 million in 2019 and $18.9
GeekWire
FEBRUARY 24, 2021
Seattle-based Adaptive Biotechnologies, which develops technology to sequence the human immune system to diagnose and treat disease, posted revenue of $30.2 The company’s quarterly net loss more than doubled to $44.6 million, and net loss grew to $146.2 Adaptive Biotech Graphic). million from $68.6 million a year earlier.
Expert insights. Personalized for you.
104 
Let's personalize your content